We describe a 53-year-old woman with hormone receptor-positive, HER2-negative breast cancer and newly diagnosed type 2 diabetes mellitus who developed NF eight days after receiving her first cycle of dose-dense doxorubicin and cyclophosphamide. Here, ERBB2 is linked to breast carcinoma.